Company Legal Name
Latest Valuation
Founded Year
Headquarter
Persist AI operates an AI-powered laboratory that develops long-acting injectable drug formulations through advanced robotics and automation technologies. Founded in 2022 and headquartered in West Sacramento, the company addresses critical challenges in pharmaceutical development by accelerating the traditionally lengthy and costly process of creating sustained-release drug delivery systems. By combining artificial intelligence with automated laboratory processes, Persist AI enables pharmaceutical companies to rapidly prototype and optimize injectable formulations that can extend dosing intervals from daily to weekly or monthly administration. The company focuses on transforming drug delivery development through its integrated platform of machine learning algorithms and robotic experimentation capabilities.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.





